人類免疫球蛋白（pH4）靜脈注射市場：按類型、疾病、通路和地區分類

Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type, By Disease Indication, By Distribution Channel and by Region

出版日期: 2026年04月27日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年靜脈注射人類免疫球蛋白（pH4）的市場規模估計為885.6億美元，預計到2033年將達到2,083.4億美元。預計從2026年到2033年，其複合年成長率將達到13.0%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	885.6億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	13.00%	2033年市場規模預測：	2083.4億美元

市場動態

大型企業擴大採用非內部成長策略，例如夥伴關係與聯盟，以增強其市場地位，預計這將推動預測期內的市場成長。例如，2020年1月，血漿衍生生技藥品生產商和分銷商ADMA Biologics, Inc.與一家未公開的合作夥伴公司簽訂了一項為期五年的生產和供應協議，由後者生產和銷售源自ADMA免疫球蛋白（IG）生產流程的血漿中間體。根據該協議，ADMA Biologics, Inc.將透過向基於其已經過核准的生產流程開發治療產品的第三方銷售在其自有工廠生產的血漿，實現每公升血漿分離收益的最大化。

本研究的主要特點：

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新藥上市和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對全球靜脈注射人類免疫球蛋白 (pH4) 市場的主要參與者進行了分析：公司概況、財務表現、產品系列、市場地位、分銷策略、關鍵發展、戰略和未來計劃。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的藥物上市、擴大適應症、市場擴張和行銷策略做出明智的決策。
這份名為《全球靜脈注射人類免疫球蛋白（pH4）市場》的報告針對的是該行業的各種相關人員，包括經銷商、供應商、製藥製造商、分銷商、新參與企業和金融分析師。
相關人員可以透過利用分析全球人類免疫球蛋白（pH4）靜脈注射製劑市場中使用的各種戰略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

Takeda Pharmaceutical Company Limited
Baxter
CSL
Bayer AG
Grifols, SA
Octapharma Brasil Ltda
Shanghai RAAS Blood Products Co Ltd
Hualan Biological Engineering, Inc.
Top Bio Group Co, Ltd（A subsidiary of China Biologic Products Holdings, Inc）
China Resources Boya Bio-pharmaceutical Group Co Ltd
ADMA Biologics, Inc.
Sinopharm Group Co. Ltd

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI3790

Human Immunoglobulin (pH4) for Intravenous Injection Market is estimated to be valued at USD 88.56 Bn in 2026 and is expected to reach USD 208.34 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.0% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 88.56 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	13.00%	2033 Value Projection:	USD 208.34 Bn

Market Dynamics

The increasing adoption of inorganic growth strategies such as partnerships and collaborations by key players to enhance their market presence is expected to propel the market growth during the forecast period. For instance, in January 2020, ADMA Biologics, Inc., a manufacturer, and distributor of plasma-derived biologics, entered a 5-year manufacturing and supply agreement with an undisclosed partner to produce and sell plasma-derived intermediate fractions from ADMA's Immune Globulin (IG) manufacturing process. Under this agreement, ADMA Biologics, Inc. will maximize the revenue per liter of plasma fractionated in its plant by selling the fractioned plasma to a third party to develop their therapeutic products under their own licensed manufacturing processes.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human immunoglobulin (pH4) for intravenous injection market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study are Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Hualan Biological Engineering Inc, China Biologic Products, Inc., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Boya Bio-Pharmaceutical Group Co., Ltd., ADMA Biologics, Inc., and Sinopharm Group Co., Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, disease indication up-gradation, market expansion, and marketing tactics
The global human immunoglobulin (pH4) for intravenous injection market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human immunoglobulin (pH4) for intravenous injection market

Detailed Segmentation:

Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type (Revenue, USD Bn, 2021 - 2033)
IgG
IgA
IgM
Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Disease Indication (Revenue, USD Bn, 2021 - 2033)
COVID-19
Primary Immunodeficiency Disease
Immune-mediated Thrombocytopenia
Kawasaki Disease
B Chronic lymphocytic Leukemia(B-CLL)
Others
Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Takeda Pharmaceutical Company Limited
Baxter
CSL
Bayer AG
Grifols, S.A
Octapharma Brasil Ltda
Shanghai RAAS Blood Products Co Ltd
Hualan Biological Engineering, Inc
Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc)
China Resources Boya Bio-pharmaceutical Group Co Ltd
ADMA Biologics, Inc
Sinopharm Group Co. Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Type, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
IgG
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
IgA
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
IgM
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)

5. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Disease Indication, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Primary Immunodeficiency Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Immune-mediated Thrombocytopenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Kawasaki Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
B Chronic lymphocytic Leukemia(B-CLL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)

6. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Distribution Channel, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 €" 2033, (US$ Bn)

7. Global Human Immunoglobulin (pH4) for Intravenous Injection Market, By Region, 2021€"2033, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022€"2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €" 2033, (US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 €" 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021€" 2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Baxter
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
CSL
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Grifols, S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Octapharma Brasil Ltda
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Shanghai RAAS Blood Products Co Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Hualan Biological Engineering, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Top Bio Group Co, Ltd (A subsidiary of China Biologic Products Holdings, Inc)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
China Resources Boya Bio-pharmaceutical Group Co Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
ADMA Biologics, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Sinopharm Group Co. Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies